Amyris (AMRS) Trading Down 12.1%

Share on StockTwits

Amyris Inc (NASDAQ:AMRS) shares were down 12.1% on Monday . The company traded as low as $4.87 and last traded at $5.01. Approximately 5,093,736 shares were traded during trading, an increase of 33% from the average daily volume of 3,839,544 shares. The stock had previously closed at $5.70.

A number of research analysts have weighed in on AMRS shares. BidaskClub lowered shares of Amyris from a “hold” rating to a “sell” rating in a research report on Tuesday, November 13th. B. Riley cut their target price on shares of Amyris from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 14th. HC Wainwright set a $11.00 target price on shares of Amyris and gave the stock a “buy” rating in a research report on Wednesday, November 14th. Finally, Zacks Investment Research raised shares of Amyris from a “strong sell” rating to a “hold” rating in a research report on Monday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $8.83.

The stock has a market capitalization of $436.20 million, a price-to-earnings ratio of -1.64 and a beta of 0.29.

Amyris (NASDAQ:AMRS) last released its earnings results on Tuesday, November 13th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.96). The business had revenue of $14.90 million for the quarter, compared to analysts’ expectations of $46.72 million. Amyris’s revenue was down 38.4% on a year-over-year basis. During the same period last year, the company posted ($0.81) earnings per share. As a group, research analysts anticipate that Amyris Inc will post -1.34 EPS for the current year.

In related news, COO Eduardo Alvarez acquired 11,834 shares of the company’s stock in a transaction dated Thursday, December 13th. The shares were bought at an average price of $4.23 per share, for a total transaction of $50,057.82. Following the acquisition, the chief operating officer now owns 333,876 shares in the company, valued at approximately $1,412,295.48. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kathleen Valiasek acquired 23,000 shares of the company’s stock in a transaction dated Tuesday, November 27th. The shares were bought at an average price of $4.37 per share, for a total transaction of $100,510.00. Following the acquisition, the chief financial officer now owns 251,630 shares in the company, valued at approximately $1,099,623.10. The disclosure for this purchase can be found here. 21.80% of the stock is owned by insiders.

Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp increased its holdings in shares of Amyris by 17.0% during the 4th quarter. Bank of New York Mellon Corp now owns 134,975 shares of the biotechnology company’s stock worth $451,000 after purchasing an additional 19,587 shares during the period. BlackRock Inc. increased its holdings in shares of Amyris by 50.2% during the 4th quarter. BlackRock Inc. now owns 3,419,786 shares of the biotechnology company’s stock worth $11,421,000 after purchasing an additional 1,142,354 shares during the period. Virtus ETF Advisers LLC bought a new position in shares of Amyris during the 4th quarter worth about $251,000. Pinnacle Associates Ltd. bought a new position in shares of Amyris during the 4th quarter worth about $1,154,000. Finally, Balasa Dinverno & Foltz LLC increased its holdings in shares of Amyris by 99.6% during the 4th quarter. Balasa Dinverno & Foltz LLC now owns 23,711 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 11,834 shares during the period. Institutional investors own 31.14% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Macon Daily and is the sole property of of Macon Daily. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://macondaily.com/2019/02/11/amyris-amrs-trading-down-12-1.html.

Amyris Company Profile (NASDAQ:AMRS)

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Recommended Story: NASDAQ

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply